Annette Bak
Head of Advanced Drug Delivery AstraZeneca
Annette Bak, Ph.D., MBA, leads Advanced Drug Delivery (ADD) at AstraZeneca and serves on the Pharmaceutical Sciences leadership team. ADD, a global organization with over 100 employees in Sweden, UK, and US, aims to transform diverse modalities into investigational medicines.
Since joining AstraZeneca in 2016, Annette has delivered various synthetic modalities and mRNA drug delivery systems for preclinical and clinical studies. She has also built delivery chemistry, intracellular drug delivery capabilities, and a search and evaluation group within ADD.
Previously, Annette worked for Amgen and Merck in the US, focusing on small molecule and peptide formulations, outsourcing partnerships in China, and in-licensing and partnership evaluations. She contributed to bringing small molecule therapies to market.
Annette has published over 50 articles, given more than 50 invited presentations, and serves on the editorial boards of the Journal of Pharmaceutical Sciences and Molecular Pharmaceutics. She holds several patents for pharmaceutical technologies.
A key volunteer in the American Association of Pharmaceutical Scientists (AAPS), Annette was the 2022 president, leading the implementation of the 2021-2025 strategic plan. She was the 2020 co-recipient of the AAPS Alice E. Till Women in Pharmaceutical Science Recognition.
Seminars
- How to effectively design patient-centric peptide delivery formulations (oral vs injectable)?
- How to ensure novel peptide formulations can be scalable and cost efficient during the manufacturing process?
- Where will delivery innovations take the peptide field in the next 5 years?
